Therapeutics News and Research

RSS

UMMS scientists identify new genetic mutation that causes familial ALS

A new genetic mutation that causes familial amyotrophic lateral sclerosis (ALS), a fatal neurological disorder also known as Lou Gehrig's Disease, has been identified by a team of scientists led by researchers at the University of Massachusetts Medical School (UMMS).

16 Jul 2012

Study shows why co-morbid conditions can result in impaired vision

Hypertension frequently coexists in patients with diabetes. A new University of Georgia study shows why the co-morbid conditions can result in impaired vision.

14 Jul 2012

New paper documents discovery of novel lipids, including MC3

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, and collaborators announced today the publication of a scientific paper documenting the discovery of novel lipids used in second generation lipid nanoparticles (LNPs) for systemic delivery of RNAi therapeutics.

14 Jul 2012

Scientists isolate new type of energy-burning fat cell

Scientists at Dana-Farber Cancer Institute have isolated a new type of energy-burning fat cell in adult humans which they say may have therapeutic potential for treating obesity.

13 Jul 2012

OncoMed commences dosing in OMP-54F28 Phase I clinical trial for advanced solid tumor cancers

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells, or tumor-initiating cells, today announced that patient dosing has begun in a Phase I clinical trial of OMP-54F28 in patients with advanced solid tumor cancers.

13 Jul 2012

Discovery sheds light on why human body is unable to fight off HIV infection

University of Washington researchers have made a discovery that sheds light on why the human body is unable to adequately fight off HIV infection.

13 Jul 2012

Oligodendroglia cells: An interview with Jeffrey Rothstein

There are three principle cells in the brain: neurons and two types of glial cells. One type is called an astrocyte. These were well known to inactivate neurotransmitters like glutamate, and provide metabolic support to neurons.

11 Jul 2012

Arrowhead initiates Adipotide Phase 1 trial in obesity

Arrowhead Research Corporation, a targeted therapeutics company, today announced that the first patient has been dosed in a Phase 1 clinical trial with Adipotide, a new class of treatment for obesity.

11 Jul 2012

ImmunoGen announces start of IMGN853 Phase I trial for ovarian cancer, other solid tumors

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN853 product candidate.

11 Jul 2012

Neonate blood-brain barrier more intact than adults following stroke

The ability for substances to pass through the blood-brain barrier is increased after adult stroke, but not after neonatal stroke, according to a new study the UCSF that will be published July 11 in the Journal of Neuroscience.

11 Jul 2012

Study details development of first mouse model for Usher syndrome III

A new study published in the July 11 issue of the Journal of Neuroscience details the development of the first mouse model engineered to carry the most common mutation in Usher syndrome III causative gene (Clarin-1) in North America.

11 Jul 2012

SRI International receives DoD grant to develop novel therapy for MS

The Department of Defense (DoD) has awarded SRI International a one-year grant to develop a novel therapy for multiple sclerosis (MS), an autoimmune nervous system disease that affects about 400,000 people in the United States and more than two million people worldwide. There is currently no cure for this disorder, which can impair vision and movement.

11 Jul 2012

Activity levels best reflect functional capacity of back pain patients

The level of physical activity displayed by an elderly individual with chronic low back pain is a better predictor for functional capacity than psychosocial factors, results from a community-based study indicate.

10 Jul 2012

ImmunoCellular receives Japanese patent allowance for brain cancer technology

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of a Japanese patent relating to a technology for the treatment of brain cancer for which the Company holds an exclusive, worldwide license.

10 Jul 2012

MammaPrint more cost-effective and clinically-useful test than Oncotype DX

New research from University of the Sciences' Mayes College of Healthcare Business and Policy suggests that MammaPrint - a gene expression profiling (GEP) test used to identify whether women with early-stage breast cancer would benefit from chemotherapy - is the more cost-effective and clinically-useful test than the most frequently used GEP in practice in the United States today.

10 Jul 2012

Blocking a fundamental process deep within cancer cells can selectively kill them

Investigators reporting in the July issue of the Cell Press journal Cancer Cell have found that blocking a fundamental process deep within cancer cells can selectively kill them and spare normal cells.

10 Jul 2012

PsiOxus closes Series B round of equity financing

PsiOxus Therapeutics, Ltd. announced that it has closed a Series B round of equity financing totaling £22 million ($34 million).

9 Jul 2012

NIH awards Clinical and Translational Science Award to three Texas Medical Center institutions

In 2006, three Texas Medical Center institutions were among the first in the nation to receive a Clinical and Translational Science Award (CTSA) from the National Institutes of Health (NIH) to accelerate the translation of laboratory discoveries into patient treatments. That grant has been renewed for another 5 years.

7 Jul 2012

ADCT, CRT sign agreements to develop ADCs against cancer

Cancer Research Technology (CRT), the commercial arm of Cancer Research UK, and Switzerland-based ADC Therapeutics Sarl (ADCT) announce today that they have signed agreements to develop cancer treatments called Antibody Drug Conjugates (ADCs) using CRT antibodies and peptides, and ADCT's 'warhead' and linker chemistries.

6 Jul 2012

Cancer Therapeutics announces validation and performance of CTx-294886 plus Avastin

Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin (bevacizumab - Genentech/Roche) in a preclinical model of breast cancer.

5 Jul 2012